In this role, Dr. Zvonić will oversee manufacturing for all of WindMIL’s cell therapies, ensuring the company supplies product to meet the demands of several upcoming clinical studies, and ultimately, position WindMIL therapeutic candidates for commercialization.

 

“Sanjin brings to WindMIL more than 15 years of experience in the development and manufacturing of cell-based therapeutics, with an impressive scientific and technical background in physiology, stem cell biology, and cell therapy CMC development. At WindMIL, we’re always looking to the future of cancer immunotherapy, so Sanjin’s ability to bridge research and manufacturing makes him an ideal fit for us as we deliver both the current generation of MILs™ and look toward developing the next generation,” said Don Hayden, Interim chief executive officer and executive chairman of WindMIL Therapeutics. “We are also fortunate that Sanjin is very focused on people development. Having him join WindMIL during this time of growth will help ensure we develop the team to its greatest potential.”

Prior to joining WindMIL, Dr. Zvonić served as senior director and Business Leader of Clinical and Commercial Manufacturing at Hitachi Chemical Advanced Therapeutics Solutions (HCATS), LLC, as Progenitor Cell Therapy (PCT) integrated into Hitachi.